Open AccessCapabilities of preoperative targeted therapy in treatment of bone metastases in renal cancer
Author(s) -
З. А. Юрмазов,
Надежда Андреевна Лушникова,
Л. В. Спирина,
Е. А. Усынин,
Е. М. Слонимская,
И. И. Анисеня,
А. В. Богоутдинова
Publication year - 2019
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2019-15-2-35-41
Subject(s) - medicine , pazopanib , renal cell carcinoma , tolerability , targeted therapy , adverse effect , quality of life (healthcare) , kidney cancer , cancer , surgery , radiology , oncology , sunitinib , nursing
The study objective is to evaluate the effectiveness of preoperative targeted therapy, spectrum and rate of adverse events, as well as quality of life in patients with bone metastases of renal cell carcinoma. Materials and methods. The study was conducted at the Research Institute of Oncology, Tomsk Medical Research Center between 2014 and 2018. The study included 34 patients with bone metastases of renal cell carcinoma who received preoperative targeted therapy with pazopanib for 8 weeks. All patients underwent surgical treatment of both the primary tumor and bone metastases. Results and conclusion. It was shown that preoperative targeted therapy is characterized by a high rate of clinical response and satisfactory tolerability. In some cases, preoperative targeted therapy improves the conditions for surgical treatment of metastatic bone lesions, decreases intraoperative blood loss, decreases the volume and duration of surgical intervention, which, in turn, allows to preserve bigger range of motion in the affected bone segment and improve patients’ quality of life.